Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP4B1 | P13584 | 2/20 | 0.46 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.46 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.46 |
| ▸ | CYP2A7 | P20853 | 2/20 | 0.46 |
| ▸ | CYP3A7 | P24462 | 2/20 | 0.46 |
| ▸ | CYP2F1 | P24903 | 2/20 | 0.46 |
| ▸ | CYP2C18 | P33260 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP2J2 | P51589 | 2/20 | 0.46 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.46 |
| ▸ | CYP4F8 | P98187 | 2/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18255792 | 0.81 | SQOR (0.50) | ADORA2AADORA1ALDH1A1 | |
| SCHEMBL24330236 | 0.81 | TDO2 (0.49) | CYP1A1CYP1A2CYP2E1CYP3A4CYP2C8 | |
| SCHEMBL7579760 | 0.78 | CASR (0.58) | CYP1A1CYP1A2CYP2E1CYP3A4CYP2C8 | |
| SCHEMBL28866454 | 0.78 | CYP1A1 (0.53) | CYP1A1CYP1A2CYP2E1CYP3A4CYP2C8 | |
| SCHEMBL24767284 | 0.78 | ACHE (0.53) | CYP1A1CYP1A2CYP2E1CYP3A4CYP2C8 | |
| SCHEMBL18244619 | 0.77 | ALDH1A1 (0.45) | CYP3A4ALDH1A1CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL16297083 | 0.76 | CYP1A1 (0.51) | CYP1A1CYP1A2CYP2E1CYP3A4CYP2C8 | |
| SCHEMBL10014741 | 0.76 | AKR1C3 (0.49) | CYP1A1CYP1A2CYP2E1CYP3A4CYP2C8 | |
| SCHEMBL28189326 | 0.76 | CYP1A2 (0.54) | CYP1A1CYP1A2CYP2E1CYP3A4CYP2C8 | |
| SCHEMBL14763343 | 0.75 | KDM4E (0.46) | CYP2A6ADORA2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3802492-B1 | COMPOUNDS USEFUL IN THE TREATMENT OF DISORDERS ASSOCIATED WITH MUTANT RAS | THE INSTITUTE OF CANCER RES ROYAL CANCER HOSPITAL (GB) | 2024-11-06 | — | — | EP | disclosed |
| US-11970469-B2 | Compounds useful in the treatment of disorders associated with mutant RAS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-04-30 | — | — | US | disclosed |
| US-20210214322-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF DISORDERS ASSOCIATED WITH MUTANT RAS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-07-15 | — | — | US | disclosed |
| US-20210214322-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF DISORDERS ASSOCIATED WITH MUTANT RAS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-07-15 | — | — | US | disclosed |
| EP-3802492-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF DISORDERS ASSOCIATED WITH MUTANT RAS | Oxford University Innovation Limited (GB) | 2021-04-14 | — | — | EP | disclosed |
| WO-2019234405-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF DISORDERS ASSOCIATED WITH MUTANT RAS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2019-12-12 | — | — | WO | disclosed |
| WO-2019234405-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF DISORDERS ASSOCIATED WITH MUTANT RAS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2019-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210214322-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF DISORDERS ASSOCIATED WITH MUTANT RAS | KRAS, NRAS, HRAS | CYP1A1 2522/4885CYP1A2 3358/4885CYP2E1 2859/4885 |
| US-11970469-B2 | Compounds useful in the treatment of disorders associated with mutant RAS | KRAS, NRAS, HRAS | CYP1A1 2522/4885CYP1A2 3358/4885CYP2E1 2859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.